Astellas pulls EU filing for telavancin
This article was originally published in Scrip
Executive Summary
Astellashas withdrawn the EU marketing authorisation application for its lipoglycopeptide antibiotic telavancin for the treatment of complicated skin and soft tissue infections (CSSTI). The decision came just a few weeks before a US advisory committee is scheduled to consider the product.